Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 8Other hematologic neoplasm 7Myeloid 2CNS 2Thoracic 1Sarcoma 1Other solid neoplasm 1

Conditions

Sarcoma 1Rhabdomyosarcoma 1Malignant mesenchymal tumor 1

Interventions

Specimen Handling 27Magnetic Resonance Spectroscopy 23Cyclophosphamide 16Biopsy 15Doxorubicin 14pembrolizumab 12X-Rays 12Radiation 12Radiotherapy 10Temozolomide 9Phantoms, Imaging 9Vincristine 7Irinotecan 7Nivolumab 6Ifosfamide 6atezolizumab 5Gemcitabine 5palbociclib 4liposomal doxorubicin 4fludarabine 4cemiplimab 4cabozantinib 4Immunoglobulin G 4Imatinib Mesylate 4Etoposide 4Dactinomycin 4Carboplatin 4Bevacizumab 4selinexor 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Filgrastim × Sarcoma × 30 days × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡